Proteomic profiling of advanced melanoma patients to predict therapeutic response to anti-PD-1 therapy.
Nina ZilaOssia M EichhoffIrene SteinerThomas MohrAndrea BileckPhil Fang ChengAlexander LeitnerLudovic C J GilletTatjana SajicSandra GoetzeBetty FriedrichPatricia BortelJohanna StroblRené ReitermaierSabrina A HoganJulia Martínez GómezRamon StaegerFelix TuchmannSophie PetersGeorg StaryMario KuttkeAdelheid Elbe-BuergerChristoph HoellerRainer KunstfeldWolfgang WeningerBernd WollscheidReinhard DummerLars Einar FrenchChristopher GernerRuedi AebersoldMitchell Paul LevesqueVerena PaulitschkePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Ultimately, this multilayered serum analysis led to a potential marker signature with 10 key markers significantly altered in at least two independent serum cohorts: CRP, LYVE1, SAA2, C1RL, CFHR3, LBP, LDHB, S100A8, S100A9, and SAA1, which will serve as the basis for further investigation. In addition to patient serum, we analyzed primary melanoma tumor cells from NR and found a potential marker signature with 4 key markers: LAMC1, PXDN, SERPINE1, and VCAN.